Christian Heidbreder Sells 18,586 Shares of Indivior (NASDAQ:INDV) Stock

Indivior PLC (NASDAQ:INDV) insider Christian Heidbreder sold 18,586 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $41.14, for a total value of $764,628.04. Following the transaction, the insider owned 209,337 shares of the company’s stock, valued at approximately $8,612,124.18. This represents a 8.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Indivior Trading Up 0.0%

Shares of INDV opened at $40.23 on Wednesday. Indivior PLC has a 1-year low of $15.00 and a 1-year high of $42.81. The firm’s 50-day moving average price is $38.60 and its 200-day moving average price is $35.07. The firm has a market capitalization of $4.90 billion, a price-to-earnings ratio of 20.63 and a beta of 0.86.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The company had revenue of $317.00 million during the quarter. On average, research analysts forecast that Indivior PLC will post 4.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

INDV has been the subject of a number of research analyst reports. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Weiss Ratings cut Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 9th. Finally, Barclays assumed coverage on Indivior in a report on Thursday, June 18th. They issued an “overweight” rating and a $46.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $40.29.

Institutional Trading of Indivior

Several hedge funds and other institutional investors have recently made changes to their positions in INDV. Salomon & Ludwin LLC purchased a new position in Indivior during the fourth quarter valued at $30,000. Harbor Capital Advisors Inc. grew its stake in shares of Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after acquiring an additional 781 shares during the last quarter. Quarry LP purchased a new stake in shares of Indivior in the third quarter worth $26,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after acquiring an additional 460 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Indivior by 544.6% during the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock valued at $43,000 after acquiring an additional 1,013 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.